The US biotech firm Loyal is developing novel longevity candidates LOY-001, LOY-002, and LOY-003 to modulate insulinlike growth factor 1 and metabolic pathways in senior dogs via injectable and oral formats, with the objective of extending canine healthspan and informing preventive aging therapies.
Key points
- LOY-001 injectable and LOY-003 chewable target IGF-1 reduction in senior large-breed dogs.
- LOY-002 metabolic modulator in large-scale trial of 1,200 dogs across 70 clinics to enhance healthspan.
- Drugs work by lowering IGF-1 signaling and improving metabolic resilience to extend healthy canine years.
Why it matters: These pioneering canine longevity therapies signal a shift towards preventive age-management in veterinary medicine and offer a translational model for human anti-aging interventions.
Q&A
- What is IGF-1?
- Why focus on dogs?
- How do LOY-001 and LOY-003 differ?
- What measures define healthspan in these trials?
